Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Incyte Corporation (INCY) vs TeraWulf Inc (WULF) Price & Performance

Incyte CorporationTrade
TeraWulf IncTrade

Price performance (Past 24H)

Key statistics

Incyte Corporation vs TeraWulf Inc — how do they compare? Incyte Corporation trades at $120.56 (market cap $24.54B), while TeraWulf Inc trades at $17.14 (market cap $8.35B). The key difference: Incyte Corporation is far larger — about 2.9× TeraWulf Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals.

INCYWULF
Market Cap
$24.54B$8.35B
Sector
HealthTechnology
52-Week High
$129.93$28.98
52-Week Low
$81.61$5.24
Enterprise Value
$20.04B$10.97B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Incyte Corporation

Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.

Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.

TeraWulf Inc

WULF trades at $17.04, up 5.19% on the day amid a broader neocloud infrastructure rally. The stock shows bearish technical signals with 17 sell signals versus 2 buys, while fundamentals reveal significant challenges with a -1,179.94% net income margin and consistent earnings misses. Recent Q2 2026 results showed a $0.37 per share loss versus $0.20 expected, though revenue beat estimates. The company is expanding its high-performance computing capacity with 102 MW operational and 336 MW under construction, supported by a major Anthropic leasing agreement.

Despite unanimous analyst buy ratings and a $38 consensus price target representing 123% upside, WULF faces substantial execution risks and profitability concerns. The transition to AI infrastructure offers long-term potential, but near-term losses and high capital requirements create volatility. Investors should weigh the significant growth opportunity against persistent negative cash flow and competitive pressures in the evolving data center market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY

About TeraWulf Inc

TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.

Read more on WULF